Nakai K, Itoh C, Nakai K, Saito F, Ninomiya K, Sato M, Sudo M
Department of Clinical Pathology, Iwate Medical University, Morioka.
Rinsho Byori. 1997 Nov;45(11):1067-71.
ACE inhibitor is known to have a therapeutic efficacy in renal diseases by reducing proteinuria and maintaining renal function. However, the relationship between ACE gene polymorphism and renal disease has not been fully elucidated. In this study, a 287 base pair(bp) I/D polymorphism of the ACE gene was examined with polymerase chain reaction(PCR) in 100 healthy subjects, 34 patients with chronic glomerulonephritis(CGN), 29 with chronic renal failure(CRF) and 25 with diabetes mellitus(DM) with(13) and without(12) nephropathy. We also measured serum ACE activity of these patients. ACE genotype and derived allele frequencies in each disease group did not differ significantly from those in healthy subjects. In all disease groups, values of serum ACE activity were higher in genotype DD than in genotype II. These findings suggest no significant association between I/D polymorphism of the ACE gene and renal disease. Further studies are needed to clarify these findings, considering renal function and type of renal disease.
已知血管紧张素转换酶（ACE）抑制剂通过减少蛋白尿和维持肾功能对肾脏疾病具有治疗效果。然而，ACE基因多态性与肾脏疾病之间的关系尚未完全阐明。在本研究中，采用聚合酶链反应（PCR）检测了100名健康受试者、34例慢性肾小球肾炎（CGN）患者、29例慢性肾衰竭（CRF）患者以及25例伴有（13例）和不伴有（12例）肾病的糖尿病（DM）患者的ACE基因287个碱基对（bp）的插入/缺失（I/D）多态性。我们还测量了这些患者的血清ACE活性。各疾病组的ACE基因型和衍生等位基因频率与健康受试者相比无显著差异。在所有疾病组中，DD基因型的血清ACE活性值高于II基因型。这些发现表明ACE基因的I/D多态性与肾脏疾病之间无显著关联。考虑到肾功能和肾脏疾病类型，需要进一步研究以阐明这些发现。
